1. Plant-derived compounds that target histone acetyltransferases inhibit Trypanosoma cruzi proliferation and viability and affect parasite ultrastructure.
- Author
-
Bortolami FP, Zuma AA, de Souza W, and Motta MCM
- Subjects
- Cell Proliferation drug effects, Animals, Antiprotozoal Agents pharmacology, Enzyme Inhibitors pharmacology, Trypanocidal Agents pharmacology, Trypanosoma cruzi drug effects, Trypanosoma cruzi ultrastructure, Anacardic Acids pharmacology, Histone Acetyltransferases antagonists & inhibitors, Curcumin pharmacology, Phenanthrenes pharmacology, Diterpenes pharmacology, Epoxy Compounds pharmacology
- Abstract
Trypanosoma cruzi, the causative agent of Chagas disease, exhibits a chromatin structure and organization similar to that of other eukaryotes, undergoing certain epigenetic modifications, such as histone acetylation and deacetylation. Histone acetyltransferase inhibitors have been frequently applied as therapy agents against tumor cells, but their effects on protozoa have not yet been adequately explored. In this study, the effects of three acetyltransferase inhibitors, curcumin, triptolide and anacardic acid, were investigated on T. cruzi. Curcumin was able to inhibit epimastigote and amastigote proliferation and was the most effective compound. Triptolide also impaired T. cruzi proliferation and, along with curcumin, promoted the unpacking of nuclear heterochromatin and nucleolus disorganization. Anacardic acid did not alter parasite growth or viability, but caused ultrastructural changes, such as mitochondrial swelling and cristae enlargement. None of these compounds affected the microtubule cytoskeleton. These findings indicate that histone acetyltransferase inhibitors, especially curcumin, display the potential to be applied in chemotherapeutic studies against T. cruzi. Our results reinforce the necessity of developing new compounds that can be used successfully in therapy against neglected diseases., Competing Interests: Declaration of Competing Interest This manuscript was approved by all authors and reports unpublished data that is not under consideration for publication elsewhere. There is no competing interesting to declare and ethical approval is not required in this work, (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF